FBXO32 and rheumatoid arthritis: RA increased skeletal muscle MAFbx/Atrogin-1, MuRF1, IGFBP3, and IGFBP5 expression, and IGF-1 treatment attenuated the increase of MAFbx/Atrogin-1, MuRF1, and IGFBP3, but not IGFBP5 [162].